In another immunocompetent mice model of subcutaneous MFC tumors study, combined treatment with apatinib and PD-L1 blockade synergistically delayed tumor growth and improved survival rates in MFC tumor-bearing immunocompetent mice. This evidence concerns the gene CD274 and neoplasm.